2.62
0.14 (5.65%)
0.14 (5.65%)
Upgrade to Real-Time
Afterhours (Closed)
Volume | 8,179,670 |
|
|||||
News | - | ||||||
Day High | 2.65 | Low High |
|||||
Day Low | 2.49 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sorrento Therapeutics Inc | SRNE | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.55 | 2.49 | 2.65 | 2.63 | 2.48 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
20,448 | 8,179,670 | $ 2.61 | $ 21,308,674 | - | 1.15 - 9.63 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:57 | formt | 333 | $ 2.62 | USD |
Sorrento Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 1.02B | 388.95M | 384.46M | $ 52.90M | $ - | -1.43 | -1.70 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 460.00k | 26.90% |
Sorrento Therapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SRNE Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.68 | 2.945 | 2.47 | 2.65 | 8,834,408 | -0.06 | -2.24% |
1 Month | 2.60 | 3.09 | 2.34 | 2.65 | 8,892,677 | 0.02 | 0.77% |
3 Months | 1.62 | 3.09 | 1.35 | 2.20 | 10,361,044 | 1.00 | 61.73% |
6 Months | 3.14 | 3.215 | 1.15 | 2.14 | 9,780,847 | -0.52 | -16.56% |
1 Year | 8.91 | 9.63 | 1.15 | 3.56 | 7,701,707 | -6.29 | -70.59% |
3 Years | 2.13 | 21.26 | 1.15 | 7.39 | 13,177,585 | 0.49 | 23.0% |
5 Years | 1.75 | 21.26 | 1.15 | 7.18 | 8,743,211 | 0.87 | 49.71% |
Sorrento Therapeutics Description
Sorrento Therapeutics Inc is a biotechnology company focused on the development of novel immunotherapies for oncology and autoimmune/inflammation diseases. The antibody technologies target various locations: extracellular, intracellular, and membrane-bound antigens. The product portfolio consists of BioSimilar/BioBetter antibodies, CAR-T programs for the treatment of solid tumors, adoptive cellular therapies, immuno-oncology mAbs, and antibody-drug conjugates. |